Annual report [Section 13 and 15(d), not S-K Item 405]

Accounts Payable (Tables)

v3.25.4
Accounts Payable (Tables)
 12 Months Ended
Dec. 31, 2025
Payables and Accruals [Abstract]  
Schedule of Accounts Payable

Accounts payable consists of the following:

 

    As of           As of        
    December 31, 2025     %     December 31, 2024     %  
Accounts payable to Cytovance   $ 25,000       3 %   $ 1,183,000       31 %
Accounts payable to University of Minnesota     500,000       67 %     712,000       18 %
Legal services firm     —       0 %     1,505,000       39 %
Other accounts payable     223,000       30 %     453,000       12 %
Total accounts payable   $ 748,000             $ 3,853,000          
Schedule of Accounts Payable to Related Party

The details of the Company’s accounts payable to Cytovance Biologics, Inc., were as follows:

 Schedule of Accounts Payable to Related Party

             
    Year Ending  
    December 31, 2025     December 31, 2024  
Beginning balance   $ 1,183,000     $ 3,515,000  
Invoices, net     743,000       2,335,000  
Payments in cash     (1,054,000 )     (3,857,000 )
Payments in common stock, at fair value     —       (810,000 )
Payments in pre-funded warrants, at fair value     (847,000 )     —  
Ending balance   $ 25,000     $ 1,183,000